431 related articles for article (PubMed ID: 16843668)
21. Synthesis and biological evaluation of 1,2,5-oxadiazole N-oxide derivatives as hypoxia-selective cytotoxins.
Monge A; López de Ceráin A; Ezpeleta O; Cerecetto H; Dias E; Di Maio R; González M; Onetto S; Seoane G; Suescun L; Mariezcurrena R
Pharmazie; 1998 Nov; 53(11):758-64. PubMed ID: 9853357
[TBL] [Abstract][Full Text] [Related]
22. Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: novel, hypoxia-selective HIF-1α inhibitors with strong antiestrogenic potency.
Buravchenko GI; Scherbakov AM; Dezhenkova LG; Bykov EE; Solovieva SE; Korlukov AA; Sorokin DV; Monzote Fidalgo L; Shchekotikhin AE
Bioorg Chem; 2020 Nov; 104():104324. PubMed ID: 33142432
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives.
Moreno E; Ancizu S; Pérez-Silanes S; Torres E; Aldana I; Monge A
Eur J Med Chem; 2010 Oct; 45(10):4418-26. PubMed ID: 20656380
[TBL] [Abstract][Full Text] [Related]
25. New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Deleuze-Masquefa C; Moarbess G; Khier S; David N; Gayraud-Paniagua S; Bressolle F; Pinguet F; Bonnet PA
Eur J Med Chem; 2009 Sep; 44(9):3406-11. PubMed ID: 19278757
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, cytotoxic evaluation, and QSAR study of some 6H-indolo[2,3-b]quinoxaline derivatives.
Moorthy NS; Karthikeyan C; Trivedi P
J Enzyme Inhib Med Chem; 2010 Jun; 25(3):394-405. PubMed ID: 20233012
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and cytotoxicity of 2-methyl-4, 9-dihydro-1-substituted-1H-imidazo[4,5-g]quinoxaline-4,9-diones and 2,3-disubstituted-5,10-pyrazino[2,3-g]quinoxalinediones.
Yoo HW; Suh ME; Park SW
J Med Chem; 1998 Nov; 41(24):4716-22. PubMed ID: 9822542
[TBL] [Abstract][Full Text] [Related]
28. New pyrazolic compounds as cytotoxic agents.
Bouabdallah I; M'Barek LA; Zyad A; Ramdani A; Zidane I; Melhaoui A
Nat Prod Res; 2007 Apr; 21(4):298-302. PubMed ID: 17479417
[TBL] [Abstract][Full Text] [Related]
29. Novel Cu(II) quinoxaline N1,N4-dioxide complexes as selective hypoxic cytotoxins.
Torre MH; Gambino D; Araujo J; Cerecetto H; González M; Lavaggi ML; Azqueta A; López de Cerain A; Vega AM; Abram U; Costa-Filho AJ
Eur J Med Chem; 2005 May; 40(5):473-80. PubMed ID: 15893021
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and in vitro antitumor activity of new quinoxaline derivatives.
Corona P; Carta A; Loriga M; Vitale G; Paglietti G
Eur J Med Chem; 2009 Apr; 44(4):1579-91. PubMed ID: 18774202
[TBL] [Abstract][Full Text] [Related]
31. Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.
Hay MP; Hicks KO; Pchalek K; Lee HH; Blaser A; Pruijn FB; Anderson RF; Shinde SS; Wilson WR; Denny WA
J Med Chem; 2008 Nov; 51(21):6853-65. PubMed ID: 18847185
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent.
Noolvi MN; Patel HM; Bhardwaj V; Chauhan A
Eur J Med Chem; 2011 Jun; 46(6):2327-46. PubMed ID: 21458891
[TBL] [Abstract][Full Text] [Related]
33. 1, 2, 4-Triazine N-oxide derivatives: studies as potential hypoxic cytotoxins. Part III.
Cerecetto H; González M; Risso M; Saenz P; Olea-Azar C; Bruno AM; Azqueta A; De Ceráin AL; Monge A
Arch Pharm (Weinheim); 2004 May; 337(5):271-80. PubMed ID: 15095420
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, structure and hypoxic cytotoxicity of 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
Jiang F; Weng Q; Sheng R; Xia Q; He Q; Yang B; Hu Y
Arch Pharm (Weinheim); 2007 May; 340(5):258-63. PubMed ID: 17464965
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives.
Desplat V; Moreau S; Belisle-Fabre S; Thiolat D; Uranga J; Lucas R; de Moor L; Massip S; Jarry C; Mossalayi DM; Sonnet P; Déléris G; Guillon J
J Enzyme Inhib Med Chem; 2011 Oct; 26(5):657-67. PubMed ID: 21250818
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives.
Moarbess G; Deleuze-Masquefa C; Bonnard V; Gayraud-Paniagua S; Vidal JR; Bressolle F; Pinguet F; Bonnet PA
Bioorg Med Chem; 2008 Jul; 16(13):6601-10. PubMed ID: 18513976
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives as hypoxic selective anti-tumor agents.
Hu Y; Xia Q; Shangguan S; Liu X; Hu Y; Sheng R
Molecules; 2012 Aug; 17(8):9683-96. PubMed ID: 22890172
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
Siim BG; Atwell GJ; Anderson RF; Wardman P; Pullen SM; Wilson WR; Denny WA
J Med Chem; 1997 Apr; 40(9):1381-90. PubMed ID: 9135035
[TBL] [Abstract][Full Text] [Related]
40. Q39, a novel synthetic Quinoxaline 1,4-Di-N-oxide compound with anti-cancer activity in hypoxia.
Weng Q; Wang D; Guo P; Fang L; Hu Y; He Q; Yang B
Eur J Pharmacol; 2008 Mar; 581(3):262-9. PubMed ID: 18215659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
